Alembic Pharmaceuticals Limited (IN:APLLTD)
:APLLTD
Want to see IN:APLLTD full AI Analyst Report?
APLLTD Stock Chart & Stats
₹930.30
-₹4.90(-0.46%)
At close: 4:00 PM EST
₹930.30
-₹4.90(-0.46%)
Day’s Range― - ―
52-Week Range₹635.30 - ₹1,107.80
Previous CloseN/A
Volume60.71K
Average Volume (3M)9.71K
Market Cap
₹147.64B
Enterprise Value₹163.75B
Total Cash (Recent Filing)₹1.55B
Total Debt (Recent Filing)₹14.89B
Price to Earnings (P/E)31.3
Beta1.04
Next Earnings
May 06, 2026EPS Estimate
8.66Next Dividend Ex-DateN/A
Dividend Yield1.28%
Share Statistics
EPS (TTM)8.70
Shares Outstanding196,563,130
10 Day Avg. Volume3,953
30 Day Avg. Volume9,706
Financial Highlights & Ratios
PEG Ratio-5.74
Price to Book (P/B)3.40
Price to Sales (P/S)2.64
P/FCF Ratio-37.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)41.24
Revenue Forecast (FY)₹82.36B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthA sustained ~13.2% revenue growth rate signals expanding market share and product adoption across geographies. Over a 2–6 month horizon this supports scale benefits, steady top-line momentum, and underpins reinvestment capacity for R&D and commercialization initiatives.
Improving Margins And Strong ROENotable improvements in gross and EBIT margins combined with a robust ROE indicate the company is capturing pricing or mix benefits and using equity capital efficiently. These durable operational gains support sustainable profitability if maintained through disciplined cost controls.
Diversified Business Model Across SegmentsA business mix spanning branded domestic formulations, international generics and an in-house API business reduces reliance on any single revenue stream. This structural diversification cushions revenue volatility and creates internal supply synergies that can preserve margins long term.
Bears Say
Declining Free Cash FlowRising capex and a falling free cash flow to net income ratio weaken cash generation. Over months this reduces financial flexibility for dividends, M&A or R&D funding and raises the probability the firm must rely more on external financing or slower organic investment pacing.
Increasing LeverageAn uptick in debt-to-equity increases fixed interest obligations and financial risk. Persisting higher leverage over the medium term can constrain strategic options, elevate refinancing risk in tighter credit markets, and reduce resilience to earnings volatility.
Net Margin Volatility / Cost Control IssuesFluctuating net margins point to inconsistent cost absorption or pricing pressure in certain product lines. Over 2–6 months this undermines earnings predictability and could pressure cash flows if management cannot stabilize costs or improve product mix in competitive generics markets.
Alembic Pharmaceuticals Limited News
APLLTD FAQ
What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?
Alembic Pharmaceuticals Limited lowest stock price was ₹635.30 and its highest was ₹1107.80 in the past 12 months.
What is Alembic Pharmaceuticals Limited’s market cap?
Alembic Pharmaceuticals Limited’s market cap is ₹147.64B.
When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?
Alembic Pharmaceuticals Limited’s upcoming earnings report date is May 06, 2026 which is in 8 days.
How were Alembic Pharmaceuticals Limited’s earnings last quarter?
Alembic Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported ₹8.7 earnings per share for the quarter, beating the consensus estimate of ₹8.372 by ₹0.328.
Is Alembic Pharmaceuticals Limited overvalued?
According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued.
Does Alembic Pharmaceuticals Limited pay dividends?
Alembic Pharmaceuticals Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 1.28%. See more information on Alembic Pharmaceuticals Limited dividends here
What is Alembic Pharmaceuticals Limited’s EPS estimate?
Alembic Pharmaceuticals Limited’s EPS estimate is 8.66.
How many shares outstanding does Alembic Pharmaceuticals Limited have?
Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.
What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?
Alembic Pharmaceuticals Limited reported an EPS of ₹8.7 in its last earnings report, beating expectations of ₹8.372. Following the earnings report the stock price went up 1.409%.
Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:APLLTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Technical Analysis
GlaxoSmithKline Pharmaceuticals Limited
―
JB Chemicals & Pharmaceuticals Ltd.
―
Jubilant Pharmova Limited
―
Marksans Pharma Limited
―
NATCO Pharma Limited
―